Paolo Baili1, Francesca Di Salvo2, Francesco de Lorenzo3, Francesco Maietta4, Carmine Pinto5,6, Vera Rizzotto4, Massimo Vicentini7,8, Paolo Giorgi Rossi7,8, Rosario Tumino9, Patrizia Concetta Rollo9, Giovanna Tagliabue10, Paolo Contiero10, Pina Candela11, Tiziana Scuderi11, Elisabetta Iannelli3, Stefano Cascinu6, Fulvio Aurora12, Roberto Agresti13, Alberto Turco1, Milena Sant1, Elisabetta Meneghini1, Andrea Micheli1,14. 1. Analytic Epidemiology and Health Impact Unit, Fondazione IRCCS "Istituto Nazionale dei Tumori", Via Venezian 1, 20133, Milan, Italy. 2. Analytic Epidemiology and Health Impact Unit, Fondazione IRCCS "Istituto Nazionale dei Tumori", Via Venezian 1, 20133, Milan, Italy. francesca.disalvo@istitutotumori.mi.it. 3. Federazione italiana delle Associazioni di Volontariato in Oncologia - FAVO, Via Barberini 11, 00187, Rome, Italy. 4. Centro Studi Investimenti Sociali (CENSIS), Piazza di Novella 2, 00199, Rome, Italy. 5. Medical Oncology, University Hospital of Parma, Via Gramsci 14, 43100, Parma, Italy. 6. Italian Association of Medical Oncologists (AIOM), Via Noè 23, 20133, Milan, Italy. 7. Inter-institutional Epidemiology Unit, AUSL Reggio Emilia, Via Amendola 2, 42122, Reggio Emilia, Italy. 8. Arcispedale Santa Maria Nuova, IRCCS, Viale Umberto I 50, 42123, Reggio Emilia, Italy. 9. Ragusa Cancer Registry, Azienda Sanitaria Provinciale Ragusa, Via Dante 109, 97100, Ragusa, Italy. 10. Varese Cancer Registry, Fondazione IRCCS "Istituto Nazionale dei Tumori", Via Venezian 1, 20133, Milan, Italy. 11. Trapani Cancer Registry, Via Ammiraglio Staiti 95, 91100, Trapani, Italy. 12. Associazione Senza Limiti, Via dei Carracci 2, 20149, Milan, Italy. 13. Breast Surgery Unit, Fondazione IRCCS "Istituto Nazionale dei Tumori", Via Venezian 1, 20133, Milan, Italy. 14. Scientific Direction, Fondazione IRCCS "Istituto Nazionale dei Tumori", Via Venezian 1, 20133, Milan, Italy.
Abstract
PURPOSE: To illustrate the out-of-pocket (OOP) costs incurred by a population-based group of patients from 5 to 10 years since their cancer diagnosis in a country with a nationwide public health system. METHODS: Interviews on OOP costs to a sample of 5-10 year prevalent cases randomly extracted from four population-based cancer registries (CRs), two in the north and two in the south of Italy. The patients' general practitioners (GPs) gave assurance about the patient's physical and psychological condition for the interview. A zero-inflated negative binomial model was used to analyze OOP cost determinants. RESULTS: Two hundred six cancer patients were interviewed (48 % of the original sample). On average, a patient in the north spent €69 monthly, against €244 in the south. The main differences are for transport, room, and board (TRB) to reach the hospital and/or the cancer specialist (north €0; south €119). Everywhere, OOP costs without TRB costs were higher for patients with a low quality of life. CONCLUSIONS: Despite the limited participation, our study sample's characteristics are similar to those of the Italian cancer prevalence population, allowing us to generalize the results. The higher OOP costs in the south may be due to the scarcity of oncologic structures, obliging patients to seek assistance far from their residence. Implications for cancer survivors Cancer survivors need descriptive studies to show realistic data about their status. Future Italian and European descriptive studies on cancer survivorship should be based on population CRs and involve GPs in order to approach the patient at best.
PURPOSE: To illustrate the out-of-pocket (OOP) costs incurred by a population-based group of patients from 5 to 10 years since their cancer diagnosis in a country with a nationwide public health system. METHODS: Interviews on OOP costs to a sample of 5-10 year prevalent cases randomly extracted from four population-based cancer registries (CRs), two in the north and two in the south of Italy. The patients' general practitioners (GPs) gave assurance about the patient's physical and psychological condition for the interview. A zero-inflated negative binomial model was used to analyze OOP cost determinants. RESULTS: Two hundred six cancer patients were interviewed (48 % of the original sample). On average, a patient in the north spent €69 monthly, against €244 in the south. The main differences are for transport, room, and board (TRB) to reach the hospital and/or the cancer specialist (north €0; south €119). Everywhere, OOP costs without TRB costs were higher for patients with a low quality of life. CONCLUSIONS: Despite the limited participation, our study sample's characteristics are similar to those of the Italian cancer prevalence population, allowing us to generalize the results. The higher OOP costs in the south may be due to the scarcity of oncologic structures, obliging patients to seek assistance far from their residence. Implications for cancer survivors Cancer survivors need descriptive studies to show realistic data about their status. Future Italian and European descriptive studies on cancer survivorship should be based on population CRs and involve GPs in order to approach the patient at best.
Entities:
Keywords:
Cancer prevalence; Cancer registry; Cancer survivorship; Out-of-pocket costs
Authors: Carla Parry; Erin E Kent; Angela B Mariotto; Catherine M Alfano; Julia H Rowland Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-10 Impact factor: 4.254
Authors: Paolo Baili; Josette Hoekstra-Weebers; Elke Van Hoof; Hans Helge Bartsch; Luzia Travado; Miklos Garami; Francesca Di Salvo; Andrea Micheli; Piret Veerus Journal: Eur J Cancer Date: 2012-12-10 Impact factor: 9.162
Authors: A Micheli; E Mugno; V Krogh; M J Quinn; M Coleman; T Hakulinen; G Gatta; F Berrino; R Capocaccia Journal: Ann Oncol Date: 2002-06 Impact factor: 32.976
Authors: L Dal Maso; S Guzzinati; C Buzzoni; R Capocaccia; D Serraino; A Caldarella; A P Dei Tos; F Falcini; M Autelitano; G Masanotti; S Ferretti; F Tisano; U Tirelli; E Crocetti; R De Angelis; S Virdone; A Zucchetto; A Gigli; S Francisci; P Baili; G Gatta; M Castaing; R Zanetti; P Contiero; E Bidoli; M Vercelli; M Michiara; M Federico; G Senatore; F Pannozzo; M Vicentini; A Bulatko; D R Pirino; M Gentilini; M Fusco; A Giacomin; A C Fanetti; R Cusimano Journal: Ann Oncol Date: 2014-08-22 Impact factor: 32.976
Authors: Matthias Büttner; Susanne Singer; Leopold Hentschel; Stephan Richter; Peter Hohenberger; Bernd Kasper; Dimosthenis Andreou; Daniel Pink; Kathy Taylor; Karin Arndt; Martin Bornhäuser; Jochen Schmitt; Markus K Schuler; Martin Eichler Journal: Support Care Cancer Date: 2021-07-11 Impact factor: 3.603